RegeneRx Announces TB4 Stroke Study to be Honored at American Heart Association Scientific Sessions
14 Setembro 2010 - 10:08AM
Business Wire
RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (“the
Company” or “RegeneRx”) today announced that the abstract entitled
Treatment of Acute Stroke With Thymosin β4 has been honored with a
score in the top 10 percent of all abstracts presented at the
American Heart Association’s specialty conferences during the year,
and therefore has been selected for re-presentation as a poster at
the AHA’s Scientific Sessions on November 15. The Scientific
Sessions will be held in Chicago from November 13 through 17.
“We congratulate Dr. Daniel C. Morris, senior staff physician,
Department of Emergency Medicine, Henry Ford Health Systems and his
team on this recognition of their important work,” said J.J.
Finkelstein, president and chief executive of RegenerRx. “With more
than 20,000 attendees at this significant conference, this poster
presentation will provide greater visibility and broader reach for
the potential use of Tβ4 to treat stroke. This exposure is
particularly welcome at this time as we formulate our plans to
advance Tβ4 into the clinic for various CNS indications and hold
strategic partnership discussions,” Mr. Finkelstein added.
The research was performed under a Material Transfer Agreement
between RegeneRx Biopharmaceuticals, Inc. and the Henry Ford Health
System and was originally presented at the International Stroke
Conference, San Antonio, TX, in February of this year. Dr. Morris
and his researchers showed that TB4, administered to rats one day
after embolic stroke, improved neurological functional outcome
compared to control animals. Improvement in neurological function
was measured at various time intervals over a seven week period and
was statistically significant.
About Tβ4
Tβ4 is a synthetic version of a naturally occurring peptide
present in virtually all human cells. It is a first-in-class
multi-functional molecule that has been shown in pre-clinical
studies to promote progenitor and endothelial cell differentiation
and migration in the heart and central nervous system, promote
cardiac and neuronal repair, angiogenesis in dermal and cardiac
tissues, increase keratinocyte migration and collagen deposition,
and decrease inflammation by down-regulating inflammatory
cytokines. RegeneRx has identified several molecular variations of
Tβ4 that may affect the aging of skin, among other properties, and
could be important candidates as active ingredients in
pharmaceutical and consumer products. Researchers at the National
Institutes of Health and various academic researchers throughout
the world have published numerous scientific articles in high
impact journals indicating Tβ4’s in vitro and in vivo efficacy in
accelerating wound healing and tissue protection and regeneration
under a variety of conditions. Abstracts of scientific papers
related to Tβ4’s mechanisms of action can be viewed at
www.regenerx.com.
About RegeneRx
Biopharmaceuticals, Inc.
RegeneRx is focused on the development of a novel therapeutic
peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection,
repair and regeneration. Currently RegeneRx has three products
in clinical development. RGN-352 is an injectable formulation to
treat cardiovascular and central nervous system diseases, as well
as other medical indications. RegeneRx has successfully completed a
Phase 1 clinical trial with RGN-352. RGN-259 is a sterile,
preservative-free topical eye drop for ophthalmic indications.
RegeneRx is currently supporting a physician-sponsored Phase 2 dry
eye study evaluating RGN-259. RGN-137, a topical gel formulation,
is currently being evaluated by RegeneRx in a Phase 2 clinical
trial for the treatment of epidermolysis bullosa. Other potential
uses for RGN-137 include the treatment of chronic dermal wounds and
reduction of scar tissue. Based on strong efficacy data in
pre-clinical studies, RegeneRx is initially targeting RGN-352 for
the treatment of patients who have suffered an acute myocardial
infarction, or heart attack. In addition to this indication, recent
pre-clinical efficacy data suggests that RGN-352 may also benefit
patients with multiple sclerosis and stroke. RegeneRx also has a
preclinical product candidate, RGN-457, which is an inhaled
formulation targeting cystic fibrosis and other pulmonary diseases.
In addition to the four pharmaceutical product candidates described
above, RegeneRx is pursuing the commercial development of peptide
fragments of Tβ4 for potential cosmeceutical use. RegeneRx holds 75
issued patents and has 261 patent applications pending worldwide
related to its products and holds an exclusive worldwide license
for Tβ4 from the National Institutes of Health.
Forward-Looking
Statements
Any statements in this press release that are not historical
facts are forward-looking statements made under the provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve risks and uncertainties that
could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. You are urged to consider
statements that include the words “project,” “believe,”
“anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,”
“would,” “could,” “will,” ”may,” “potential” or the negative of
those words or other similar expressions words to be uncertain and
forward-looking. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risks and uncertainties
inherent in our business, including, without limitation the risk
that our product candidates do not demonstrate safety and/or
efficacy in future clinical trials; risks related to our ability to
obtain financing to support our operations on commercially
reasonable terms; the progress, timing or success of our clinical
trials; difficulties or delays in development, testing, obtaining
regulatory approval for producing and marketing our product
candidates; regulatory developments; the size and growth potential
of the markets for our product candidates and our ability to serve
those markets; the scope and validity of patent protection for our
product candidates; competition from other pharmaceutical or
biotechnology companies; and other risks described in the Company’s
filings with the Securities and Exchange Commission (“SEC”),
including those identified in the “Risk Factors” sections of the
annual report on Form 10-K for the year ended December 31, 2009,
and the quarterly report on Form 10-Q for the quarter ended June
30, 2010, as well as other filings it makes with the SEC. Any
forward-looking statements in this press release represent the
Company’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
The Company anticipates that subsequent events and developments may
cause its views to change, and the Company specifically disclaims
any obligation to update this information, as a result of future
events or otherwise, except as required by applicable law.
Regenerx Biopharm In (AMEX:RGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Regenerx Biopharm In (AMEX:RGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024